Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Factor VIII

Criteria

Inclusion Criteria:

• Diagnosed with congenital haemophilia A or B with inhibitors to factor VIII or factor IX

• Treated with room temperature stable NovoSeven®